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Wednesday, February 24, 2010 755athe residues are close to each other in closed, open or inactivated states. With
this technique, we have detected and analyzed molecular movements within the
voltage-sensor domain, between the voltage sensor and the pore domain, and
within the pore domain.Minisymposium 4: New Chemical Modulators by
Rational Design
3927-MiniSymp
Optimizing Ligand-Protein Interactions Via Silcs: Site Identification by
Ligand Competitive Saturation
Alexander MacKerell.
Univ Maryland, Baltimore, MD, USA.
Fragment-based methods for drug optimization have great potential; however,
time, expense and sensitivity considerations associated with NMR and x-ray
crystallographic based methods limit their applicability. As an alternative we
have developed a computational approach, SILCS: Site Identification by
Ligand Competitive Saturation, that uses explicit solvent all-atom molecular
dynamics to identify binding sites on protein surfaces for functional groups.
Information from the SILCS approach may then be combined with structural
information on an inhibitor-protein complex to facilitate modification of the
ligand to improve its binding affinity. An overview of SILCS and its application
to inhibitor-ligand optimization will be presented.
3928-MiniSymp
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific
Drug Binding
Stephen G. Aller.
Univ. Alabama at Birmingham, Birmingham, AL, USA.
P-glycoprotein (Pgp) detoxifies cells by exporting hundreds of chemically unre-
lated toxins but causesmultidrug resistance in the treatment of cancers. Substrate
promiscuity is a hallmarkof Pgp activity, thus a structural descriptionof polyspe-
cific drug-binding is vital for the rational design of anticancer drugs and MDR
inhibitors. The x-ray structure of apo-Pgp at 3.8 A˚ reveals an internal cavity of
~6,000 A˚3 with a 30 A˚ separation of the two nucleotide binding domains
(NBD). Two additional Pgp structures with novel cyclic peptide inhibitors dem-
onstrate distinct drug binding sites in the internal cavity capable of stereo-selec-
tivity that is based on hydrophobic and aromatic interactions. Apo- and drug-
bound Pgp structures have portals open to the cytoplasm and the inner leaflet
of the lipid bilayer for drug entry. The inward-facing conformation represents
an initial stage of the transport cycle that is competent for drug binding.
3929-MiniSymp
Chemical Synthesis of a Highly Selective Probe of the Renal Outer
Medullary Potassium Channel (ROMK)
Jerod S. Denton, Brian A. Chauder, Rishin Kadakia, Eric S. Dawson,
Craig W. Lindsley, C. David Weaver, Gautam Bhave.
Vanderbilt University School of Medicine, Nashville, TN, USA.
The renal outer medullary potassium channel, ROMK, critically regulates salt
and water balance and may be a drug target for a novel class of diuretic. How-
ever, the molecular pharmacology of the inward rectifier potassium channel
family is virtually undeveloped, precluding assessment of ROMK’s therapeutic
potential. We therefore performed a high-throughput screen of approximately
225,000 small molecules for modulators of ROMK function, from which sev-
eral novel antagonists were identified. One compound, termed VU590, inhibits
ROMK with a half-inhibition concentration (IC50) of 300 nM, has no effect on
Kir2.1 or Kir4.1, but inhibits Kir7.1 at low micromolar concentrations. Two
structurally related compounds were identified in the screen, but were found
to be comparatively weak ROMK inhibitors. Using a molecular mechanics-
based knowledge of VU590, medicinal chemistry was employed to improve
the potency of one compound 33-fold (IC50 from 8 mM to 240 nM). This novel
probe, termed VU591, is highly selective for ROMK over Kir2.1, Kir2.3,
Kir4.1, Kir6.2/SUR1B, Kir7.1 and a panel of more than 65 other potential
off-targets, including voltage-gated sodium and calcium channels and hERG.
Functional studies suggest the VU591 binding site is located in the cytoplasmic
pore of ROMK. VU591 will be instrumental in mapping the location and topo-
graphical features of this selective binding site and could pave the way for an-
imal studies assessing the therapeutic potential of ROMK.
3930-MiniSymp
Gold Nanoparticles as a Platform for Designing Protein-Protein Interac-
tion Inhibitors: Application to Ubiquitin-Like Modifications
Yang Su, Angela Perkins, Yi-Jia Li, Yuelong Ma, David Horne, Yuan Chen.
Beckman Research Institute of the City of Hope, Duarte, CA, USA.Inhibitors of non-covalent protein-protein interactions hold much promise as
useful probes to our understanding of human biology and disease mechanisms,
as well as leads for developing new therapies. Developing such inhibitors, how-
ever, continues be a significant challenge. Protein-protein interactions mediated
by ubiquitin-like (Ubl) modifications are among the most important signalling
and regulatory mechanisms that control nearly every aspect of cellular func-
tions. A unique feature of these post-translational modifications is the forma-
tion of poly-Ubl chains; however, strategies to target these poly-Ubl chain
modified proteins are lacking. In this study, we show that gold nanparticles
(AuNPs) conjugated with small molecule inhibitors can selectively target
such poly-Ubl chains. Virtual ligand screening was carried out to identify small
molecule mimmetics of the Small Ubiquitin-like MOdifier (SUMO) interaction
motif in order to inhibit SUMO-mediated down-stream effects. Virtual ligand
screening was based on the NMR structure of SUMO in complex with a peptide
containing the SUMO-interaction motif. Interactions of the hit compounds with
SUMO were investigated by NMR methods. One of the hits was modified for
conjugation to an AuNP by adding a thiol tail. While the individual compounds
do not have high affinity for SUMO (having Kd of 2 mM), conjugation of ap-
proximately 100 compounds to one AuNP allows for multi-valent interactions
between AuNP and multiple SUMO proteins in a poly-SUMO chain; thus effi-
ciently inhibits poly-SUMO-chain-mediated protein-protein interactions. This
study demonstrates a viable approach to creating highly effective inhibitors
by using AuNPs as a platform for multivalent interactions. This is the first
application of AuNP for inhibiting Ubl modifications and provides a novel ap-
proach to specifically and effectively address such types of Ubl modifications
for future research and therapeutic applications.
3931-MiniSymp
New Approaches to Anti-Infective and Anti-Cancer Therapeutics
Targeting Metalloproteins
Eric Oldfield.
university of illinois at urbana, urbana, IL, USA.
I will give an account of recent progress in the development of novel anti-in-
fectives targeting isoprenoid biosynthesis. Topics to be covered include: carot-
enoid biosynthesis as a target in staph and malaria; novel inhibitors of bacterial
farnesyl and undecaprenyl diphosphate synthase; and the mechanism of action
of the Fe4S4 cluster-containing proteins, GcpE (IspG) and LytB (IspH). We
have investigated the mechanism of action and inhibition of Aquifex aeolicus
LytB using a combination of site-directed mutagenesis (KM, Vmax), EPR and
1H, 2H, 13C, 31P and 57Fe-ENDOR. The EPR and ENDOR results support
formation of an initial pi/sigma ‘‘metallacycle’’ complex similar to that ob-
served previously with allyl alcohol bound to a nitrogenase FeMo cofactor.
The complex is poised to interact with the E126 CO2H group, resulting in
loss of H2O and formation of eta1 and/or eta3-allyl complexes. The IPP and
DMAPP products are then formed in a second Hþ/e- reduction step. We also
report that alkyne diphosphates are inhibitors of IspH and likewise form pi
or pi/sigma metallacycle complexes, as evidenced by 1H, 2H, and 13C
ENDOR. I will also give an update on the mechanism of action of GcpE,
and the discovery of potent, mechanism-based, inhibitors of this enzyme.Platform BF: Cardiac Muscle II
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Proteomics of the Human Cardiac Intercalated Disc: A More Complex
Multi-Functional Structure than was Previously Thought
Cristobal G. dos Remedios1, Colleen Estigoy2, Darryl Cameron3,
Joshua W.K. Ho3, Benjamin Herbert4, Matthew Padula4, Russel Pickford5,
Michael Guilhaus5, Jacob Odeberg6, Fredrik Ponten7.
1University of Sydney, Sydney, Australia, 2Bosch Institute (F13), The
University of Sydney, Sydney, Australia, 3The University of Sydney, Sydney,
Australia, 4University of Technology Sydney, Sydney, Australia, 5University
of New South Wales, Kensington, Australia, 6Royal Institute of Technology,
Stockholm, Sweden, 7University of Uppsala, Uppsala, Sweden.
The intercalated disc (ICD) of cardiac muscle joins one cardiomyocyte to sev-
eral others. It transmits contractile force between these heart muscle cells, but it
also must allow action potentials, ions and even small molecules to cross the
junctions, it contains multiple receptors, and must permit the cardiomyocytes
to grow. The literature contains 142 proteins in mammalian hearts that were
identified using a wide range of techniques. Here we employ two technologies
that nearly double this number. We use Fourier transform mass spectrometry to
identify 84 proteins based on an analysis of their tryptic peptides using purified
(but not pure) ICDs from human left ventricles from four non-failing hearts,
only about half of which (43) were previously known. We then explore the
Human Proteome Atlas (HPA) database to identify 162 ICD proteins using
756a Wednesday, February 24, 2010its>6000 anti-human polyclonal, affinity-purified antibodies of which 49 were
identified by MS and 79 were novel. HPA antibodies were available for 82 the
142 proteins but only 43 reacted positively with the ICDs based on immunohis-
tochemistry. We supplement these approaches with 14 proteins identified using
conventional 2-DE. Combining all techniques. Only 14 proteins were common
to the MS data, HPA antibodies and the literature. We can categorize all 273
identified ICD proteins according to their known functions and demonstrate
their functional interactions in a single inter-active relationship according to
their functions: (i) adhesion, anchoring and binding (88); (ii) enzymes (46);
(iii) proteins that maintain the structure and function of the ICDs (35); (iv) myo-
fibrillar (34); (v) channels (32); (vi) ligands and their receptors (18); (vii) cyto-
plasm proteins (6); and (viii) mechanoreceptors (4). We will now extend these
analyses to ICD proteins that change as a result of human heart failure.
3933-Plat
Quantitative Analysis of MyBP-C Phosphorylation in Human Heart using
Phosphate Affinity SDS-Page
Steven Marston1, Sakthivel Sadayappan2, O’neal Copeland1.
1Imperial College London, London, United Kingdom, 2Loyola University
Chicago, Chicago, IL, USA.
Phosphorylation sites in Cardiac MyBP-C have been predicted at Ser273,282
and 302 but studies in intact tissue have identified 5 phosphorylted sites and
suggested up to 4.6molsPi/mol MyBP-C is present in human heart.
We analysed MyBP-C phosphospecies in human heart myofibrils by phosphate
affinity SDS-PAGE using a non-specific antibody raised against the MyBP-C
peptide 2-14. We observed six bands corresponding to 0, 1P, 2P, 3P, 4P, 5P
phospho-species. Control experiments with pure MyBP-C indicated that the
antibody labelled all phosphospecies equally. The assigned phosphorylation
levels were confirmed by staining western blots with PhosTools phosphopro-
tein stain. This separation permits direct quantitative determination of
MyBP-C phosphospecies without need for calibration.
In donor heart myofibrils the highly phosphorylated species predominated: 0,
753%: 1P, 151%: 2P, 2357%: 3P, 4152%: 4P, 2058% (n=4) from which
total phosphorylation of MyBP-C was calculated to be 3.4molsPi/mol. In fail-
ing heart unphosphorylated MyBP-C predominated (0, 4854%: 1P, 454%:
2P, 2755%: 151%: 3P, 1754%: 4P, 452%, n=4) and calculated total phos-
phorylation was 1.5 molsPi/mol. Total phosphorylation in failing heart myofi-
brils was 44% of donor and in myectomy samples from HCM patients it was
29% of donor, compared with 45 and 40% respectively determined in previous
assays.
We conclude that MyBP-C is highly phosphorylated in vivo with significant
phosphorylation of at least 5 sites and that phosphorylation is dynamic, being
greatly reduced in pathological muscle. Initial tests using antibodies specific
to Ser 273, 282 and 302 show distinct patterns on phosphate affinity SDS-
PAGE indicating varying preferences for the highly phosphorylated species
of MyBP-C in normal and pathological muscle.
3934-Plat
Identification of Amino Acid Residues in the Cardiac Myosin Binding
Protein-C Motif Important for Actin Binding
Justin F. Shaffer1,2, Samantha P. Harris2.
1University of Washington, Seattle, WA, USA, 2University of California,
Davis, Davis, CA, USA.
N-terminal domains of cardiac myosin binding protein-C (cMyBP-C) can acti-
vate actomyosin interactions in the absence of Ca2þ and bind to actin in a phos-
phorylation dependent manner. We have previously shown that two N-terminal
domains, C1 and the MyBP-C motif (‘‘M’’) domain, bind specifically to actin
and to thin filaments; however, the sequences or residues that mediate actin
binding have not been identified. The goal of this study was to identify residues
in the M-domain that contribute to actin binding and to investigate whether in-
teractions between the M-domain and actin mediate the activating properties of
cMyBP-C. We therefore used alanine-scanning mutagenesis to target candidate
actin binding sites in the M-domain that bear homology to the actin binding
motifs in other known actin binding proteins and to assess the effects of muta-
tions on the ability of recombinant proteins to bind actin and activate actomy-
osin interactions in motility assays. Results demonstrate that mutation of select
positively-charged amino acids in the M-domain that are homologous to bind-
ing motifs in known actin binding proteins reduced binding of cMyBP-C to
actin. The mutations also reduced or eliminated the activating properties of re-
combinant cMyBP-C in in vitro motility assays. However, mutation of other
positively-charged amino acids did not affect actin binding or protein func-
tional properties. These results indicate that specific residues within the M-do-
main confer actin binding and that interactions with actin contribute to the func-
tional effects of recombinant cMyBP-C N-terminal proteins. Supported by NIH
HL080367 to SPH and a NSF Graduate Research Fellowship to JFS.3935-Plat
N-Terminal Fragments of Cardiac Myosin Binding Protein-C Inhibit
Actomyosin Motility by Tethering Actin
Abbey E. Weith1, Sakthivel Sadayappan2, Peter VanBuren1,
Jeffrey Robbins2, David M. Warshaw1.
1University of Vermont, South Burlington, VT, USA, 2Cincinnati Children’s
Hospital Medical Center, Cincinnati, OH, USA.
Cardiac myosin binding protein-C (cMyBP-C) mutations are a leading cause of
hypertrophic cardiomyopathy. cMyBP-C has 11 domains, C0 through C10, that
bind sarcomeric proteins, including myosin and actin. A 29 kDN-terminal frag-
ment (C0C1f) of cMyBP-C containing the first two domains C0 and C1 and the
first 15 residues of the conserved MyBP-C motif is cleaved from cMyBP-C fol-
lowing ischemic-reperfusion injury (Sadayappan et al., JMCC 44:S44, 2008).
Expressed C0C1f fragments inhibit actin velocities in the motility assay at
a 2:1 molar ratio to myosin, similar to other N-terminal fragments: C0C3,
C0C2, and C1C2. Interestingly, fragments containing only the C0C1 domains
do not alter velocity, suggesting the additional 15 residues in C0C1f are neces-
sary for inhibition. Adding C0C1 to the motility assay can partially reverse the
C0C3-mediated inhibition of velocity, suggesting C0C1 may compete with
C0C3 for actin binding. cMyBP-C fragments may affect motility by creating
a tether between actin and the flowcell surface. To test this, motility experi-
ments were performed under high ionic strength, saturating MgATP, and in
the absence of methylcellulose, conditions in which most actin filaments dif-
fuse away from the surface due to weak interactions with myosin. In the pres-
ence of C0C2, many actin filaments bound and translocated on the surface, con-
firming this fragment’s tethering capacity. Additionally, in the laser trap we
adhered C0C3 fragments to a bead in the absence of myosin and observed
C0C3 transiently binding to a single actin filament with an ~100 ms attached
lifetime. We also saw evidence that C0C3 may partially unfold under load.
These experiments strongly suggest that N-terminal domains of cMyBP-C con-
taining the MyBP-C motif tether actin filaments and provide one mechanism
for modulating actomyosin motion generation, i.e. by imposing an effective
viscous load within the sarcomere.
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PKC Phosphorylation of Titin’s PEVK Element–A Novel and Conserved
Pathway for Modulating Myocardial Stiffness
Bryan D. Hudson1, Carlos G. Hidalgo1, Julius Bogomolovas2, Yi Zhu1,
Brian Anderson1, Marion Greaser3, Siegfried Labeit2, Henk L. Granzier1.
1University of Arizona, Tucson, AZ, USA, 2Universitatsmedizin, Mannheim,
Germany, 3University of Wisconsin, Madison, WI, USA.
Protein Kinase C (PKC) regulates contractility of cardiac muscle cells by phos-
phorylating multiple thin- and thick- filament based proteins, and plays key
roles in development of cardiovascular pathologies. Myocardial sarcomeres
also contain a third myofilament, titin, which we demonstrate here to also be
phosphorylated by PKC. Titin phosphorylation was observed in skinned myo-
cardial tissues following incubation with PKCa and this effect was exacerbated
~5 fold in the mouse and ~2.5 fold in the pig by preincubation with Protein
Phosphatase 1 (PP1). In vitro phosphorylation of recombinant protein repre-
senting titin’s spring elements shows that PKCa targets the PEVK spring
element. Mass spectrometry in combination with site-directed mutagenesis
identified two highly conserved sites in the PEVK region that are phosphory-
lated by PKCa (S11878 and S12022); when these two sites are mutated to
alanine, phosphorylation is effectively abolished. Mechanical experiments
with murine and porcine skinned LV myocardium revealed that PKCa
significantly increases titin-based passive tension in a sarcomere length (SL)-
dependent fashion. Single molecule force-extension curves show that PKCa
decreases the PEVK persistence length (from 1.20 nm to 0.55 nm), without
altering the contour length, and using a serially-linked wormlike chain
(WLC) model we show that this results in an ~20% increase in titin-based pas-
sive force with a SL dependence that is similar to that measured in skinned
myocardium following PKCa phosphorylation. We conclude that PKC phos-
phorylation of titin is a novel and conserved pathway that links myocardial sig-
naling and myocardial stiffness.
3937-Plat
Titin Strucure and Extensibility in Healthy and Failing Hearts
Helen K. Graham, Michael J. Sherratt, Andrew W. Trafford.
University of Manchester, Manchester, United Kingdom.
The giant sarcomeric protein, titin is the primary determinant of myocardial
passive stiffness. In failing human hearts however, it has been proposed that re-
duced myofilament passive tension is due to an altered titin isoform expression
profile1, 2. In this study we set out to directly quantify the tensile strength of titin
molecules isolated from healthy and diseased myocardium.
